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Abstract
Background: Ovarian cancer remains a significant public health burden, with the highest mortality rate of all the
gynecological cancers. This is attributable to the late stage at which the majority of ovarian cancers are diagnosed, coupled
with the low and variable response of advanced tumors to standard chemotherapies. To date, clinically useful predictors of
treatment response remain lacking. Identifying the genetic determinants of ovarian cancer survival and treatment response
is crucial to the development of prognostic biomarkers and personalized therapies that may improve outcomes for the late-
stage patients who comprise the majority of cases.
Methods: To identify constitutional genetic variations contributing to ovarian cancer mortality, we systematically
investigated associations between germline polymorphisms and ovarian cancer survival using data from The Cancer
Genome Atlas Project (TCGA). Using stage-stratified Cox proportional hazards regression, we examined w650,000 SNP loci
for association with survival. We additionally examined whether the association of significant SNPs with survival was
modified by somatic alterations.
Results: Germline polymorphisms at rs4934282 (AGAP11/C10orf116) and rs1857623 (DNAH14) were associated with stage-
adjusted survival (p= 1.12e-07 and 1.80e-07, FDR q= 1.2e-04 and 2.4e-04, respectively). A third SNP, rs4869 (C10orf116), was
additionally identified as significant in the exome sequencing data; it is in near-perfect LD with rs4934282. The associations
with survival remained significant when somatic alterations.
Conclusions: Discovery analysis of TCGA data reveals germline genetic variations that may play a role in ovarian cancer
survival even among late-stage cases. The significant loci are located near genes previously reported as having a possible
relationship to platinum and taxol response. Because the variant alleles at the significant loci are common (frequencies for
rs4934282 A/C alleles = 0.54/0.46, respectively; rs1857623 A/G alleles = 0.55/0.45, respectively) and germline variants can be
assayed noninvasively, our findings provide potential targets for further exploration as prognostic biomarkers and
individualized therapies.
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Introduction
Ovarian cancer accounts for about three percent of all cancers
in women and is the fifth leading cause of cancer-related death
among women in the United States, with an age-adjusted
incidence rate of 12.8 per 100,000 women per year and death
rate of 8.6 per 100,000 women per year (2003–2007) [1]. Of the
gynecological cancers, ovarian cancer has the highest mortality,
with an overall five-year survival rate of 43.7% for white women
and 34.9% for black women [1]. The poor survival statistics are
attributable to the late stage at which ovarian cancers are
diagnosed due to their asymptomatic nature: while stage I tumors
have a 92.4% relative survival rate, they account only for 15% of
ovarian cancer diagnoses; by contrast, stage III and IV cancers
have survival rates of 34% and 18%, respectively, and together
account for 65.4% of diagnoses [1]. Response to standard
chemotherapy (platinum plus taxane) is highly variable [2,3],
and tends to be poor for advanced cases [2]. Understanding the
genetic determinants of ovarian cancer survival and response to
treatment may improve these statistics, particularly for stage III
and IV patients who comprise the majority of cases. In particular,
identifying variations that predict response to chemotherapy
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allows for the possibility of administering alternate therapies that
may improving outcomes.
Previous studies have examined the role of genetic variation in
ovarian cancer susceptibility, progression, treatment response, and
survival. It has been shown that BRCA1/2 germline mutations
contribute to 10–15% of cases [4], and analysis of data from The
Cancer Genome Atlas Project (TCGA [5]) has also shown that
that BRCA1/2 germline mutation, somatic mutations and
promoter methylation effect ovarian cancer survival [5]. Addi-
tionally, candidate gene studies have shown that polymorphisms in
MDM2, along with TP53 status and SULF1, are associated with
ovarian cancer survival [6–8]. Recently, Huang and coworkers
reported a genetic variation is associated with carboplatin
cytotoxicity in vitro and in vivo [3], a finding which may explain
differential responsiveness to the standard platinum–based ovarian
cancer therapy. The same authors later showed that the identified
locus regulates miRNAs that contribute to platinum sensitivity,
suggesting a mechanism of action [9].
To date, however, a clinically useful genomic marker of ovarian
cancer survival remains elusive. The platinum–associated SNP
investigated by Huang was not found to be significantly associated
with survival in a validation cohort [3]. Likewise, Bolton and co-
workers successfully identified several loci associated with ovarian
cancer susceptibility, but those they initially found to be associated
with survival failed to reach significance in the validation set [10],
although it is hoped that future studies of this cohort will result in
established associations with clinical outcome [10]. While tumor
gene expression signatures predictive of treatment response and
relapse have been reported (e.g., [11,12]), their clinical utility is
limited by the cost, invasiveness, and variability inherent in
evaluating tumor gene expression. Likewise, somatic copy number
changes in certain genes have recently been reported to influence
survival [13], but the utility of measuring CNV as a prognostic test
is similarly limited.
The Cancer Genome Atlas Project (TCGA [5]) provides a
collection of genomic and clinical data in which associations
between genetics and survival can be thoroughly explored. Here,
we carry out a genome-wide analysis to systematically investigate
associations between germline genetic variation and overall survival
in TCGA patients diagnosed with ovarian cancer (serous
cystadenocarcinoma) [14]. The patients had an age and stage
distribution typical of ovarian cancer, as shown in Table 1. Using
the clinical and Affymetrix SNP6.0 (‘‘SNP6’’) genotype data, we
identified two single nucleotide polymorphism (SNP) loci at which
the germline genotype is predictive of overall survival in ovarian
cancer patients. The associations remain significant after adjusting
for stage, and are associated with survival even amongst stage III
patients. This suggests that constitutional genetic variation may
play a role in treatment response and provides a potential avenue
for a non-invasive prognostic biomarker test.
Results
Here, we report the association between germline SNPs and
patient survival using TCGA ovarian cancer data. The filtered
data comprised a total of 662,521 SNPs assayed in 489 clinically
annotated ovarian cancer samples, with stage and age distributions
as given in Table 1. Each of the 662,521 SNPs meeting the
filtration criteria were tested for association with survival using
Cox proportional hazards regression adjusted for stage using a
non-additive model. Two SNPs, rs4934282 (A/C) in the gene
AGAP11 (previously associated with C10orf116) and rs1857623
(A/G) upstream of DNAH14, showed a statistically significant
univariate association with overall ovarian cancer survival, as
summarized in Table 2. A qq plot of the p-values obtained is given
in Figure 1. We additionally computed the per-allele hazard ratios
for these SNPs using an additive model, obtaining HR=0.599
(p=1.28e-08) for the C allele at rs4934282 and HR=1.425
(p=1.70e-05) for the G allele at rs1857623. It should be noted that
due to the small sample size, the power to detect a SNP with
MAF=0.45 (as these are) with a=1e-06 is 32% for HR=0.6 and
3.5% for HR=1.4; it is therefore likely that other SNPs with
similar effect sizes may have been missed by chance in this
analysis.
To illustrate the effect of rs4934282 (AGAP11/C10orf116) and
rs1857623 (DNAH14) germline genotype on survival among
patients with similar tumor stage, Kaplan-Meier plots for the 372
Stage III patients are given in Figures 2 and 3. Notably, the CC
genotype at rs4934282 in AGAP11/C10orf116 confers a protec-
tive effect, nearly doubling the median survival time over the AA
genotype group. Additionally, patients with homozygous CC at
rs4934282 have a five-year survival rate of 45%, vs. 34% overall
for Stage III patients [1].
To further investigate variation in the genomic regions
surrounding these SNPs, we examined exome/capture sequencing
data (for 375 patients with available germline data) in 100 Kbp
windows centered about the two SNPs identified as significant in
the SNP6 data, specifically chr10:88672456–88772455 and
chr1:223081228–223181227. For ten samples with available
whole-genome data, we were able to compare the intronic
rs4934282 and rs1857623 Affymetrix SNP6.0 calls to those from
the whole-genome sequencing, confirming the validity SNP6 calls.
Of the 29 exome/capture SNPs tested (see Table 3) in the 375
samples, only rs4869 in C10orf116 remained significant after
adjusting for the multiple hypotheses (FDR q=9.89e-03). rs4869 is
located *2000b.p. upstream of rs4934282 and is in near-perfect
linkage disequilibrium with rs4934282 (A/C at rs4934282
correlating with C/T at rs4869, respectively). rs4869 encodes a
synonymous mutation in C10orf116 (Ile68Ile). We also investigat-
ed whether the variant alleles at any of these 29 loci led to
deleterious nonsynonymous protein alterations; only five SNPs
had mis-sense allelic variations, none of which were predicted to
be deleterious (Table 4).
Finally, we used data derived from normal–paired tumor
samples to assess whether the strong effect of germline genotype on
survival was significantly mediated or moderated by tumor gene
expression gain or loss of copy number in the tumor, or by loss of
heterozygosity (see File S1) to test the hypothesis that the effect of
germline genotype on ovarian cancer survival might be influenced
by somatic events. We found no significant association of tumor
gene expression, copy number variation, or loss of heterozygosity
in these regions with survival (see File S1). Rather, the large effect
of germline genotype at the loci on patient survival is independent
of these somatic changes, and appears to suggest that constitu-
tional genetic variation in these regions plays a role in treatment
response.
Discussion
Recent studies have demonstrated that common genetic
variants are associated with ovarian cancer risk [15,16]. However,
it remains difficult to predict ovarian cancer survival independent
of stage; current clinical findings show that tumor response and
extreme drug resistance in vitro are not good predictors of ovarian
cancer survival [17,18]. In our study, we comprehensively tested
the SNPs assayed in the TCGA SNP6.0 data for association with
survival, and additionally analyzed whole-genome and exome/
capture SNPs in the genomic regions surrounding the significant
Germline SNPs Predict Ovarian Cancer Survival
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SNP6.0 SNPs. We identified three SNPs in two genomic regions
that had a statistically–significant association with survival. As
shown in Table 2, the hazard ratios for homozygous minor alleles
approached or exceeded two-fold in stage-stratified Cox propor-
tional hazard models, and the per-allele effect sizes for these SNPs
using a stage-stratified additive genotype model were HR=0.599
and HR=1.425 for rs4934282 C and rs1857623 G, respectively.
Interestingly, none of the somatic variations we examined (tumor
gene expression, copy number variation, and loss of heterozygos-
ity) were associated either with the germline genotype at these loci
or with survival, despite a plausible hypothesis that somatic
changes in the tumor might have an effect on the genotype–
survival association. Rather, these SNPs are strongly predictive of
survival independent of somatic changes that had already occurred
in the tumor (see File S1).
Two of the survival–associated SNPs are located within a
2200 bp region on chromosome 10 (rs4934282 at chr10:88732476
and rs4869 at chr10:88730312) and are in near–perfect LD in this
data. This genomic region is associated with C10orf116
(chr10:88727949–88730672) and AGAP11 (chr10:88730498–
88769960), which overlap; the biological significance of the
variation probed by rs4934282 and rs4869 may be associated
with either. AGAP11 is a member of the ankyrin repeat and
GTPase domain Arf GTPase activating protein gene family [19].
C10orf116 (also referred to as APM2) is a protein of unknown
function that is homologous to the medium chain of mammalian
clathrin-associated protein complex and is involved in vesicular
transport in yeast. The genomic region containing rs4934282 and
rs4869 is shown in Figure 4.
While little prior evidence exists linking AGAP11 to cancer
susceptibility, survival, or treatment response, some evidence exists
for the role of C10orf116. C10orf116/APM2 expression has been
implicated in other gynecological cancers; for instance, is has been
shown to strongly differentiate between the BRCA1 associated
breast tumor subclasses ESR1-positive and ESR1-negative [20]
and is has been found to be downregulated in utering cancer in a
number of studies [21]. More recently, C10orf116 has been shown
to exhibit differential expression in different pathological grades of
ovarian carcinoma [22] and in the response of breast cancer to
chemotherapy [23,24].
More importantly, there exists from cell lines pointing to
C10orf116 as a mediator of cisplatin resistance. Ovarian cancer
has been treated with platinum compounds for many years
[25,26], with cisplatin and carboplatin (which has a more
acceptible toxicity profile) as a standard therapy for newly–
diagnosed stage III ovarian cancers [26,27]. However, while many
patients respond to initial treatment, the five-year survival rates
remain poor (34% overall for stage III [1]). APM2 (C10orf1116)
has been shown to promote cisplatin resistance when overex-
pressed in HCT116 cell lines that were sensitive to chemotherapy
and radiation [28], suggesting a possible mechanism by which
rs4869 and rs4934282 influence survival. Silencing of APM2 by
shRNA was shown to enhance the cytotoxic effects of cisplatin on
tumor xenografts grown in CD-1 nude mice. Additionally, APM2
was found to be overexpressed in cisplatin resistant gastric cancer
cells, but not in gastric cancer cells resistant to 5-FU or
doxorubicin [29]. More recently, it was found that rs1649942, a
SNP located *5 Mb upstream of rs4934282/rs4869, had a
modest association with carboplatin-induced cytotoxicity and the
survival of ovarian cancer patients following carboplatin-based
chemotherapy [3]. Although this SNP failed to reach significance
in their phase 2 validation analysis (and likewise not significant in
our study), it adds to the body of evidence implicating this genomic
region in platinum sensitivity.
Table 1. Stage and age at diagnosis, organized by 5-year survival.
Censored v5 yrs Survival v5 yrs Survival §5 yrs All p
N 187 (38%) 228 (47%) 74 (15%) 489
Stage 1.3e-02
I 10 2 2 14
II 11 6 8 25
III 140 181 53 374
IV 26 39 11 76
Age 58.2 (49.6, 65.5) 59.9 (51.0, 68.1) 62.3 (54.7, 71.4) 59.1 (51.4, 69.1) 6.1e-02
Stage and age at diagnosis of samples, organized by 5-year survival. Median age is reported, with the first and third quartiles given in parentheses. p values for the
univariate association between stage and survival and age and survival (logrank test) are also given.
doi:10.1371/journal.pone.0055037.t001
Figure 1. QQ plots. Quantile-quantile plot for observed p values for the likelihood ratio tests of the stage-adjusted Cox models versus the expected
distribution of p values under independent null hypotheses. Points above the line indicate values that are more significant than expected; a large
systematic deviation from this line would be indicative of population substructure driving the results. The two SNPs identified as significant,
rs4934282 and rs1857623, lie well above the line and outside the small systematic deviation.
doi:10.1371/journal.pone.0055037.g001
Germline SNPs Predict Ovarian Cancer Survival
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The third significant SNP, rs1857623, is found in an intergenic
region on chromosome 1, 53 Kb upstream of DNAH14 and
136 Kb downstream from CNIH3. DNAH14 belongs to the
dynein heavy chain family, a motor protein which attaches to
microtubules and walks along cytoskeletal microtubules [30]. The
mechanism by which variation in DNAH14 may impact survival is
less clear. One possible avenue for future studies is its potential role
in the context of taxol therapy: DNAH14 contains the microtu-
bule-binding stalk of dynein motor (pfam12777 at Location:2910–
3244 of reference protein NP_001364.1), and it has been
demonstrated that taxol binds microtubules [28]. DNAH14 has
also been found to be differentially regulated in response to taxane
therapy in gastric cancers [31] and doxorubicin therapy in
endometrial cells [32].
These findings suggest that consitutional genetic variations in
these regions may play a role in ovarian cancer survival even
among late-stage cases. However, it should be noted that the
results presented here constitute a discovery–based analysis that
did not include a validation cohort. As such, the findings may be
spurious false positives, and require confirmation in follow–up
studies. If validated, these SNPs may have important clinical
potential as prognostic biomarkers since germline genotype can be
assayed noninvasively and because the variant alleles at the
significant loci are common (frequencies for rs4934282 A/C
alleles = 0.54/0.46 respectively; rs1857623 A/G alleles = 0.55/
0.45, respectvely; both comparable to allele frequencies for the
Caucasian CEPH population in HapMap [33]). The significant
loci are located in genes previously identified as having a possible
relationship to chemotherapeutic response, suggesting that their
association with survival may be due to their influence on
treatment response. Our study suggests potential targets for
prognositic tests and individualized therapies, and provides a basis
for follow-up research.
Materials and Methods
Data
Data were collected by the TCGA project as described
elsewhere [14]. Follow-up times, vital status, tumor stage, and
Table 2. Stage-adjusted survival.
rs4934282 (AGAP11/C10orf116, chr10:88732476)
N (482) HR p q pperm
AA 146 (ref) (ref) (ref) (ref)
AC 231 0.686 8.0e-03 7.5e-01 8.4e-03
CC 105 0.355 3.6e-08 3.7e-03 v2e-06
Logrank 1.1e-07 1.2e-04 v2e-06
rs1857623 (DNAH14, chr1:223131228)
N (486) HR p q pperm
AA 151 (ref) (ref) (ref) (ref)
AG 230 0.881 3.9e-01 9.8e-01 6.8e-01
GG 105 1.999 2.9e-05 4.5e-01 1.2e-04
Logrank 1.8e-07 2.4e-04 6.6e-05
rs4869 (C10orf116, chr10:88730312)
N (304) HR p
TT 102 (ref) (ref)
CT 152 1.763 2.6e-03
CC 108 2.132 1.3e-04
Logrank 3.4e-04
Significant survival associations after stratification by stage; rs4934282 and rs1857623 are from SNP6 data, rs4869 is from exome/capture data (29 SNPs tested). All tests
of Schoefeld residuals had pw0:07, meeting the proportional hazards assumption.
doi:10.1371/journal.pone.0055037.t002
Figure 2. Survival of stage-III ovarian cancer patients by rs4934282 genotype. Kaplan-Meier survival plots for Stage III patients, stratified by
germline genotype at rs4934282 (AGAP11): AA, black; AC, blue; CC, red. Confidence intervals are shown as a shaded region around each Kaplan-Meier
curve. Censored observations are denoted with vertical ticks. The dashed horizontal and vertical lines mark 50% survival and five years (1825 days)
respectively.
doi:10.1371/journal.pone.0055037.g002
Germline SNPs Predict Ovarian Cancer Survival
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germline genotype data were obtained from the TCGA project
[14] via the data portal on 06/03/2011.
SNP6 genotypes. Genotype calls for the 906,600 SNP probes
assayed using the Affymetrix GenomeWide SNP6.0 platform and
processed using Birdseed were obtained from TCGA. Samples
that did not pass the TCGA quality control (per the TCGA copy
number Sample Data Relationship Format file) were removed. A
total of 496 ovarian serous cystadenocarcinoma patients had
survival time and germline (either blood or tumor-adjacent
normal) genotype data. Genotype calls were coded as 0, 1 or 2
according to the number of variant alleles and filtered according to
a Birdseed confidence threshold of 0.05.
The genotype data were subject to additional quality control
filtration criteria as follows. SNPs with call rates v0:95 or minor
allele frequencies v0:05 were excluded, as were SNPs out of
Hardy Weinberg equilibrium with pv10{4. All samples with a
call rate below 80% were excluded. Identity by state was
computed using the R GenABEL package, and closely related
samples with IBSw0:95 were removed. The SNP and sample
filtration criteria were applied iteratively until all samples and
SNPs met the stated thresholds. In total, 489 samples and 662,521
SNPs passed were kept in the analysis.
Tumor stage. Stage subcategories were coalesced for the
purposes of this analysis into summary stage categories yielding
four stage classifications (i.e., Stage IA, IB, IC were treated as
Stage I, etc.). The number of samples in each stage category is
given in Table 1.
Exome/capture data. Next generation exome/capture se-
quencing data were also retrieved for 375 patients with available
germline data. The analysis was restricted to 100 Kbp windows
centered about the two SNPs identified as significant in the SNP6
data, specifically chr10:88672456–88772455 and
chr1:223081228–223181227. Graphical descriptions of these
genomic regions are provided in Figures 5 and 6.
Binary Sequence Alignment/Map (BAM) files were downloaded
from dbGAP, using for each sample the largest available normal
BAM file. The ‘‘mpileup’’ and ‘‘bcftools’’ features of SAMtools
[34] were used to generate the variant call information, with
calling criteria as follows: if the coverage in a given sample for a
given locus was less than the coverage threshold (see following
paragraph), no call was made; otherwise, if non-reference allele
frequency was less than 10%, the call was ‘‘homozygous
reference;’’ if the non-reference frequency was greater than
90%, the call was ‘‘homozygous nonreference;’’ if it was between
10% and 90%, the call was ‘‘heterozygous.’’
To set the coverage threshold for the exome/capture data, we
compared the exome/capture calls to the SNP6 germline genotype
calls for 41 tag SNPs located in those regions. Treating the SNP6
calls as the gold standard for accuracy, we define the ‘‘mismatch
rate’’ to be the number of calls for exome/capture and SNP6 data
differ, divided by the total number of exome/capture calls made at
that coverage depth. As coverage threshold is increased and the
exome/capture data becomes more reliable, the mismatch rate
decreases, but fewer exome/capture calls can be made. We varied
the coverage threshold from 5 to 30, selecting the lowest coverage
that yielded a mismatch rate smaller than 0.05. The optimum
coverage was 9 (with a mismatch rate of 0.045).
We considered a locus to be informative (ie, having sufficient
variation) if at least 20 germline samples had a heterozygous call at
that coverage threshold; these criteria yield 29 total informative
SNPs in the 100 Kbp regions surrounding rs4934282 and
rs1857623, shown in Table 3, which we considered in the analysis.
Survival analysis
Survival analysis was carried out in R [35] using the ‘‘survival’’
package [36]. For each SNP represented in the data, Cox
proportional hazards regression was used to model survival as a
function of genotype. Because of the significant association of stage
with survival, all models were stratified by stage. Genotype calls
were treated as categorical variables with 0 as the referent group to
avoid imposing linearity in the number of variant alleles. Each
model yielded two hazard ratios per SNP (one for genotype = 1
with respect to genotype = 0 and another for genotype = 2 w.r.t.
genotype = 0). The significance of the association was assessed
using the logrank (Score) test [37]. A test of Schoenfeld residuals
was used to check whether the proportional hazards assumption
was met; only models with pw0:05 were considered valid. 639,510
SNPs tested met the proportional hazards assumption.
Because the large number of SNPs implies a vast number of
hypotheses being tested, multiple testing adjustments were made to
the p values. This was done in two ways. We report both the false
discovery rate [38] (q) for the p values obtained for the parametric
tests described above. In addition, we report permutation pperm
values obtained using 600,000 independent resamplings of the
data. Permutation tests, while computationally intensive, are
considered the strongest and most appropriate control of type-I
error rates in genome-wide studies [39–41].
To investigate the existence and effect of any population
stratification, the R package GenABEL [42] was used to examine
population substructure. The genomic inflation factor was
estimated to be l~1:09, indicating that population substructure,
if present, should have no appreciable effect on the results. Using a
randomly selected set of 12,000 independent (pairwise LD
r2v0:01) SNPs with MAFw0:3, population substructure was
examined using principal component analysis. Pairwise plots of the
first four components are provided in the File S2. We adjusted the
models in two ways: using the first four PCs, and using cluster
assignments identified from the PCA using R package mclust [43].
As expected based on l~1:09, we observed no appreciable
changes in the Cox model results (data not shown). The results
Figure 3. Survival of stage-III ovarian cancer patients by
rs1857623 genotype. Kaplan-Meier survival plots for Stage III
patients, stratified by germline genotype at rs1857623 (DNAH14): AA,
black; AG, blue; GG, red. Confidence intervals are shown as a shaded
region around each Kaplan-Meier curve. Censored observations are
denoted with vertical ticks. The dashed horizontal and vertical lines
mark 50% survival and five years (1825 days) respectively.
doi:10.1371/journal.pone.0055037.g003
Germline SNPs Predict Ovarian Cancer Survival
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presented here are therefore not adjusted for population substruc-
ture.
Sequencing data analysis
We compared the SNP6 genotypes at the significant loci
(chr10:88722456 and chr1:223131228) to those from whole-
genome sequencing data for 10 available samples; all 10 matched
the SNP6 calls for the significant SNPs, supporting the SNP6
genotype calls.
For the two SNPs showing significant association with
survival in the SNP6 data, we further investigated the
surrounding genomic regions using combined whole-genome
and exome/capture sequencing data. We investigated 29 SNPs
in the the genomic regions surrounding rs4934282 and
rs1857623 shown in Table 3 and chosen as described above.
Stage-stratified Cox proportional hazards models were then
constructed for the germline genotypes as described above. It
should be noted neither rs4934282 nor rs1857623 were
included due to insufficient exome/capture data (rs4934282
Table 4. SIFT and logRE predictions for missense SNPs.
substitution SIFT logRE
rsID Chr Position Gene RefSeq NT AA score prediction score prediction
rs3750823 10 88707134 MMRN2 NM_024756 c.G145A p.G49S 0.15 borderline 0.27 neutral
rs4934281 10 88692330 MMRN2 NM_024756 c.C2191G p.H731D 0.62 neutral NA NA
rs34587013 10 88686602 MMRN2 NM_024756 c.G2728C p.V910L 0.91 neutral NA NA
rs9864 10 88712378 SNCG NM_003087 c.A329T p.E110V 0.15 borderline 0.36 neutral
rs2641563 10 88758233 AGAP11 NM_133447 c.A244G p.I82V 1.00 neutral NA NA
SIFT and logRE predictions for missense SNPs. Shown are the location, gene, and RefSeq IDs for the SNPs, the nucleotide (NT) and amino acid (AA) substitutions, and the
SIFT and logRE scores and predictions. SIFT scores are classified into predictions as follows: 0.00—0.05, probably damaging; 0.051—0.10, possibly damaging; 0.101—
0.20, borderline; 0.201—1.00, neutral. logRE scores are classified into predictions as follows: 1—up, probably damaging; 0.7—0.99, possibly damaging; 0.5—0.69,
borderline; 0.0—0.49, neutral.
doi:10.1371/journal.pone.0055037.t004
Figure 4. Genomic region containing rs4934282 and rs4869. Detailed description of the genomic region of chromosome 10 containing
rs4934282 (second SNP from the right) and rs4869 (shown in green). Note the overlap between AGAP11 and C10orf116.
doi:10.1371/journal.pone.0055037.g004
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is in an intronic region and hence not assayed in the exome/
capture data; rs1857623 had no calls in the majority of
samples).
It should be noted that not all the genomic regions contributing
to these data have unique sequences. To assess this, we used the
‘‘mapability’’ criteria as implemented in CGWB [44]: for each
Figure 5. Genomic region surrounding rs4934282. Image from cgwb.nci.nih.gov of selected tracks for genome build NCBI36 (hg18) for the
region surrounding two germline variations associated with survival in ovarian cancer in C10orf116/AGAP11 region on chromosome 10. The tracks
are a custom track showing the SNPs rs4869 and rs4934282, RefSeq gene, mRNA, spliced ESTs and mapability.
doi:10.1371/journal.pone.0055037.g005
Figure 6. Genomic region surrounding rs1857623. Image from cgwb.nci.nih.gov of selected tracks for genome build NCBI36 (hg18) for the
region surrounding a germline variation associated with survival in ovarian cancer upstream of DNAH14 on chromosome 1. The tracks are a custom
track showing the SNP rs1857623, RefSeq gene, mRNA, spliced ESTs and mapability.
doi:10.1371/journal.pone.0055037.g006
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locus under consideration, we consider a sliding 75 base-pair
window containing that locus and attempt to match it to other
regions in the genome; the locus is flagged as unique if, for every
position of the sliding window, the sequence only maps to the
location of the window and no other genomic region. Loci for
which some (or all) positions of the sliding window contain
sequences that map to multiple genomic regions are flagged with a
dagger in Table 3, denoting that the reads contributing to the calls
at that locus may be nonspecific.
Prediction of amino-acid substitutions
We examined the SNPs in Table 3 for mis-sense substitutions
using program ANNOVAR [45] and predicted their functional
impact on protein sequences with logRE and SIFT. LogRE is the
log10 of the ratio of HMMER E-values for the fit to a PFAM motif
domain of two amino acid sequences that differ by an amino acid
substitution. A logRE score whose absolute value is greater than or
equal to 1 indicates that the amino acid alteration is likely to affect
protein [46]. SIFT is a sequence homology-based tool that Sorts
Intolerant From Tolerant amino acid substitutions and predicts
deleterious amino acid substitutions. SIFT values ƒ0:05 are
predicted to be deleterious [47]. Of the SNPs considered above
five mis-sense snps were identified: three in MMRN2 (rs3750823,
rs4934281, rs34587013), one in SNCG (rs9864), and one in
AGAP11 (rs2641563). However, there is no evidence that these
amino acid changes have functional impact on the proteins
(Table 4).
Analysis of somatic variations
To test the hypothesis that somatic changes might have an
additive or moderating effect on the association between germline
genotype and ovarian cancer survival, we used TCGA data
derived from paired tumor samples to assess whether tumor gene
expression, gain or loss of copy number in the tumor, or loss of
heterozygosity were significantly associated with survival. A full
description of the methods and results for this analysis is given in
the File S1. None of these additional covariates were significant.
Supporting Information
File S1 Methods and results of analysis of somatic
variations.
(PDF)
File S2 Methods and results of population substructure
analysis.
(PDF)
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